nimacimab glp-1 news Skye to develop for the treatment of obesity by targeting the endocannabinoid system Skye Q4 2025 slides: nimacimab

According to Dr Sethi, some people in clinical practice exhibit results, but this doesn't apply to everyone and relies on multiple factors such as poor eating habits, smoking and drinking alcohol regularly.

North America North America is still a mature but growing area

Large-scale compounding pathways for semaglutide and tirzepatide have narrowed substantially since early 2025

Reinforcing these findings, previous studies showed that S protein promoted tight junction degradation, endothelial cell activation and increased adherence of immune cells 23,61

Further long-term studies are required to confirm this result, particularly in patients with diabetes mellitus